The two most common prostate diseases to date are prostatitis and benign hyperplasia (BPH). Prostatitis can be complicated by BPH or may be accompanied by intermittent exacerbations. Drug treatment is an important component in the general treatment of prostate diseases. In addition, treatment often ends in failure due to improper therapy, missed medications, and neglect of the disease when the condition is relieved.
Thus, 20-30% of patients are dissatisfied with treatment, do not feel a decrease in urinary symptoms and improve quality of life. This is most likely due to poor assessment of lower urinary tract function in men with BPH and inadequate treatment choices accordingly.
As you know, prostatitis is acute and chronic (CP), bacterial and abacterial.
Prostatitis in%
- acute bacterial prostatitis - 5-10%;
- chronic bacterial prostatitis - 6-10%;
- chronic abacterial prostatitis - 80-90%, including prostatodinia - 20-30%.
The most common is chronic abacterial prostatitis, which requires timely prevention and control of exacerbations with and without BPH.
The main drugs for the treatment of BPH and chronic prostatitis:
- 5a-reductase inhibitors (finasteride, dutasteride);
- α-blockers (doxazosin, tamsulosin);
- phytotherapy (sabal palm extract);
- antibiotics;
- amino acid complexes;
- animal organ extracts (prostate extract);
- entomotherapy drugs (products from insects).
At the same time, 13-30% of the effects of the use of a-blockers do not occur after 3 months of treatment - additional therapy with drugs of this group is not recommended.
When prescribing finasteride, the doctor needs to prepare the most important side effects of the drug: impotence, decreased libido, decreased discharge can cause the patient to withdraw from the drug.
Treatment of BPH and prostatitis is important, an unresolved urological problem.
In the absence of surgery on the prostate gland, the frequent exacerbation of CP forces the doctor to use additional methods of drug treatment. Often, the presence of CP complicates the course of BPH, because in 80% of cases there is inflammation in the prostate gland with benign hyperplasia.
Modern medicine gives us new opportunities for the treatment of CP and BPH and the prevention of inflammation.